From the Desk of the Associate Editor: The Diverse Use of PET/CT Diagnostic Imaging for Prostate Cancer

This comprehensive review summarizes important clinical concepts in the rapidly advancing field of positron emission tomography/computed tomography (PET/CT) for prostate cancer. The authors reviewed 18F-NaF-, choline-, fluciclovine- and prostate-specific membrane antigen (PSMA)-based modalities in primary disease staging and assessment of biochemical recurrence. The most thoroughly studied modality to date is choline PET/CT.

In general, choline PET/CT performs poorly in the staging of primary disease but improves upon conventional CT and multi-parametric magnetic resonance imaging (mpMRI) in the detection of metastatic lesions in biochemical recurrence. 18F-fluciclovine and PSMA PET/CT show promise in staging both primary disease and biochemical recurrence. For all modalities, performance in the biochemical recurrence setting depends upon prostate-specific antigen (PSA) concentration: lower concentrations correspond to less precision. In addition, the clinical significance of small, occult metastases detected at lower PSA concentrations remains unclear.  

The take-home message is that clinicians should keep abreast of developments in PET/CT for prostate cancer—in particular, choline-, fluciclovine-, and PSMA-based modalities—and consider its use for assessing metastatic burden in biochemical recurrence. Further studies are forthcoming regarding its use in the assessment of primary disease.

Written by: J. Kellogg Parsons, MD, MHS, a board-certified urologist and Professor of Urology who specializes in treating prostate cancer, benign prostatic hyperplasia (BPH), bladder cancer, and kidney cancer. Dr. Parsons currently serves as a consulting editor for European Urology and European Urology Focus, and is an associate editor for Prostate Cancer and Prostatic Diseases.

Read the Full-Text Article: The Use of PET/CT in Prostate Cancer
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe